Avalyn Pharma (NASDAQ:AVLN) Upgraded at Wall Street Zen

Wall Street Zen upgraded shares of Avalyn Pharma (NASDAQ:AVLN) from a sell rating to a hold rating in a research report released on Saturday morning,Wall Street Zen reports.

Other research analysts have also issued research reports about the company. Weiss Ratings assumed coverage on Avalyn Pharma in a research report on Thursday, August 13th. They set a “sell (d+)” rating for the company. Jefferies Financial Group initiated coverage on Avalyn Pharma in a research report on Monday, May 25th. They issued a “buy” rating and a $52.00 target price on the stock. Zacks Research upgraded Avalyn Pharma to a “hold” rating in a research note on Wednesday, May 27th. Evercore assumed coverage on shares of Avalyn Pharma in a report on Tuesday, May 26th. They set an “outperform” rating and a $51.00 price target for the company. Finally, Guggenheim assumed coverage on shares of Avalyn Pharma in a research report on Monday, May 25th. They set a “buy” rating and a $80.00 price target for the company. Two equities research analysts have rated the stock with a Strong Buy rating, two have issued a Buy rating, one has issued a Hold rating and one has assigned a Sell rating to the stock. According to MarketBeat, Avalyn Pharma currently has a consensus rating of “Moderate Buy” and an average target price of $60.00.

Avalyn Pharma Stock Up 4.2%

AVLN opened at $34.98 on Friday. The company has a current ratio of 33.12, a quick ratio of 33.12 and a debt-to-equity ratio of 0.04. The stock’s 50-day simple moving average is $32.94. Avalyn Pharma has a fifty-two week low of $24.15 and a fifty-two week high of $40.17. The firm has a market capitalization of $1.55 billion and a price-to-earnings ratio of -1.53.

Avalyn Pharma (NASDAQ:AVLN) last issued its earnings results on Wednesday, August 12th. The company reported ($0.98) EPS for the quarter, beating analysts’ consensus estimates of ($1.03) by $0.05. Research analysts anticipate that Avalyn Pharma will post -3.81 earnings per share for the current year.

Institutional Inflows and Outflows

Institutional investors and hedge funds have recently modified their holdings of the business. California State Teachers Retirement System acquired a new position in shares of Avalyn Pharma during the second quarter valued at $236,000. Bank of New York Mellon Corp acquired a new stake in Avalyn Pharma in the second quarter worth about $1,321,000. Braidwell LP bought a new position in Avalyn Pharma in the 2nd quarter valued at about $26,382,000. Finally, Montanova Capital LLC bought a new position in Avalyn Pharma in the 2nd quarter valued at about $82,402,000.

Avalyn Pharma Company Profile

Avalyn Pharma is a clinical-stage biopharmaceutical company focused on developing inhaled therapies for serious and progressive pulmonary diseases. The company is working to deliver established antifibrotic medicines directly to the lungs through proprietary inhalation technologies, with the goal of improving treatment and potentially reducing systemic exposure and related side effects.

Avalyn’s lead program, AP01, is an inhaled formulation of pirfenidone being developed for patients with idiopathic pulmonary fibrosis, a chronic lung disease characterized by progressive scarring and declining respiratory function.